Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
Sign Up to like & getrecommendations! Published in 2018 at "Value in health regional issues"
DOI: 10.1016/j.vhri.2018.04.003
Abstract: OBJECTIVES The first objective is to describe current managed entry agreement (MEA) activity in the Middle East and North African (MENA) region and the pharmaceutical decision makers' perception and use of these agreements; The second… read more here.
Keywords: east north; outlook; managed entry; middle east ... See more keywords
How can managed entry agreements contribute to coverage decisions in Latin America?
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462324000527
Abstract: Abstract Context Healthcare stakeholders in Latin America, including payers, manufacturers, and patients, seek to expedite access to technologies. However, uncertainty sometimes surrounds their true benefits and budgetary implications. Managed entry agreements (MEAs) are proposed to… read more here.
Keywords: entry agreements; latin america; policy forum; uncertainty ... See more keywords
A strategic framework for synergizing managed entry agreement efforts to access pharmaceutical products in Saudi Arabia-results from a multi-stakeholder workshop.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medical economics"
DOI: 10.1080/13696998.2025.2506967
Abstract: Abstract Background Managed entry agreements (MEAs) between manufacturers and healthcare payers allow health systems to maximize patients’ access to treatments while maintaining financial sustainability. However, to work efficiently, MEAs need to be integrated into a… read more here.
Keywords: framework; pharmaceutical products; multi stakeholder; access ... See more keywords
Introduction of managed entry agreements in Korea: Problem, policy, and politics
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.999220
Abstract: Objectives: This study aimed to understand Managed Entry Agreements (MEAs) in Korea through the framework of three streams of the policy window model and its practical management and impact on pricing and reimbursement scheme. Methods:… read more here.
Keywords: problem; managed entry; introduction managed; policy ... See more keywords
Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
Sign Up to like & getrecommendations! Published in 2023 at "Healthcare"
DOI: 10.3390/healthcare11030447
Abstract: This systematic study aims at analyzing the differences between the approach of the European healthcare systems to the pharmaceutical market and the American one. This paper highlights the opportunities and the limitations given by the… read more here.
Keywords: systems across; managed entry; healthcare systems; entry agreements ... See more keywords
Opportunities and Threats of the Legally Facilitated Performance-Based Managed Entry Agreements in Slovakia: The Early-Adoption Perspective
Sign Up to like & getrecommendations! Published in 2023 at "Healthcare"
DOI: 10.3390/healthcare11081179
Abstract: Slovakia has adopted an amendment to Act No. 363/2011, regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. High expectations are associated with arrangements… read more here.
Keywords: managed entry; performance based; opportunities threats; based managed ... See more keywords